학술논문
Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment.
Document Type
Academic Journal
Author
Georgopoulos NS; Medical Faculty, School of Health Sciences, University of Thessaly, 415 00 Larissa, Greece.; Tolia M; Department of Radiotherapy, School of Medicine, University of Crete, 711 10, Heraklion, Greece.; Mauri D; Medical Oncology, University of Ioannina, Ioannina, Greece.; Kamposioras K; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.; Charalampakis N; Oncology Clinic, Metaxa Hospital, Piraeus, Greece.; Tsoukalas N; Department of Oncology, 401 General Military Hospital of Athens, Athens, Greece.; Gkantaifi A; Department of Radiotherapy, Theageneio Cancer Hospital of Thessaloniki, Greece.
Source
Publisher: Bentham Science Pub Country of Publication: United Arab Emirates NLM ID: 101270873 Publication Model: Print Cited Medium: Internet ISSN: 1876-1038 (Electronic) Linking ISSN: 15748871 NLM ISO Abbreviation: Rev Recent Clin Trials Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) decreases the risk of local recurrence after surgery in patients with locally advanced rectal cancer (LARC) and metformin is constantly gaining scientific interest due to its potentially radiosensitizing effect.
Objective: This review article aims to better clarify the role of metformin as a radiosensitizer in patients with LARC undergoing neoadjuvant concurrent chemoradiotherapy.
Methods: We used the PubMed database to retrieve journal articles and the inclusion criteria were all human studies that illustrated the effective role of metformin in the neoadjuvant setting of locally advanced rectal cancer.
Results: Our search resulted in 17 citations, of which 10 eventually fulfilled the inclusion criteria of our study. Promising results (improved tumor and nodal regression as well as higher pathologic complete response rate) have been occasionally documented with metformin use in some of the included studies. However, regarding survival and all-cause mortality, no significant difference has been found.
Conclusion: Metformin might constitute a highly promising radiosensitizer in neoadjuvant LARC treatment attracting much scientific interest. Due to the lack of studies with high evidence, further advanced research is required to enhance the existing knowledge about its potential value in this field.
(Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Objective: This review article aims to better clarify the role of metformin as a radiosensitizer in patients with LARC undergoing neoadjuvant concurrent chemoradiotherapy.
Methods: We used the PubMed database to retrieve journal articles and the inclusion criteria were all human studies that illustrated the effective role of metformin in the neoadjuvant setting of locally advanced rectal cancer.
Results: Our search resulted in 17 citations, of which 10 eventually fulfilled the inclusion criteria of our study. Promising results (improved tumor and nodal regression as well as higher pathologic complete response rate) have been occasionally documented with metformin use in some of the included studies. However, regarding survival and all-cause mortality, no significant difference has been found.
Conclusion: Metformin might constitute a highly promising radiosensitizer in neoadjuvant LARC treatment attracting much scientific interest. Due to the lack of studies with high evidence, further advanced research is required to enhance the existing knowledge about its potential value in this field.
(Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)